dc.contributor.author |
Glasgow, Matthew |
en |
dc.contributor.author |
Harding, Jane |
en |
dc.contributor.author |
Edlin, Richard |
en |
dc.date.accessioned |
2018-12-02T22:34:21Z |
en |
dc.date.issued |
2018-07 |
en |
dc.identifier.citation |
The Journal of Pediatrics 198:151-155.e1 Jul 2018 |
en |
dc.identifier.issn |
0022-3476 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/44760 |
en |
dc.description.abstract |
OBJECTIVE:To evaluate the costs of using dextrose gel as a primary treatment for neonatal hypoglycemia in the first 48 hours after birth compared with standard care. STUDY DESIGN:We used a decision tree to model overall costs, including those specific to hypoglycemia monitoring and treatment and those related to the infant's length of stay in the postnatal ward or neonatal intensive care unit, comparing the use of dextrose gel for treatment of neonatal hypoglycemia with placebo, using data from the Sugar Babies randomized trial. Sensitivity analyses assessed the impact of dextrose gel cost, neonatal intensive care cost, cesarean delivery rate, and costs of glucose monitoring. RESULTS:In the primary analysis, treating neonatal hypoglycemia using dextrose gel had an overall cost of NZ$6863.81 and standard care (placebo) cost NZ$8178.25; a saving of NZ$1314.44 per infant treated. Sensitivity analyses showed that dextrose gel remained cost saving with wide variations in dextrose gel costs, neonatal intensive care unit costs, cesarean delivery rates, and costs of monitoring. CONCLUSIONS:Use of buccal dextrose gel reduces hospital costs for management of neonatal hypoglycemia. Because it is also noninvasive, well tolerated, safe, and associated with improved breastfeeding, buccal dextrose gel should be routinely used for initial treatment of neonatal hypoglycemia. TRIAL REGISTRATION:Australian New Zealand Clinical Trials Registry: ACTRN12608000623392. |
en |
dc.format.medium |
Print-Electronic |
en |
dc.language |
eng |
en |
dc.publisher |
Elsevier |
en |
dc.relation.ispartofseries |
The Journal of Pediatrics |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
http://creativecommons.org/licenses/by-nc-nd/4.0 |
en |
dc.subject |
Children with Hypoglycemia and Their Later Development (CHYLD) Study Team |
en |
dc.subject |
Humans |
en |
dc.subject |
Hypoglycemia |
en |
dc.subject |
Glucose |
en |
dc.subject |
Gels |
en |
dc.subject |
Sweetening Agents |
en |
dc.subject |
Intensive Care, Neonatal |
en |
dc.subject |
Length of Stay |
en |
dc.subject |
Decision Trees |
en |
dc.subject |
Infant, Newborn |
en |
dc.subject |
Costs and Cost Analysis |
en |
dc.subject |
Health Resources |
en |
dc.subject |
New Zealand |
en |
dc.title |
Cost Analysis of Treating Neonatal Hypoglycemia with Dextrose Gel |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1016/j.jpeds.2018.02.036 |
en |
pubs.begin-page |
151 |
en |
pubs.volume |
198 |
en |
dc.rights.holder |
Copyright: Elsevier |
en |
dc.identifier.pmid |
29625731 |
en |
pubs.end-page |
155.e1 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
735715 |
en |
pubs.org-id |
Liggins Institute |
en |
pubs.org-id |
LiFePATH |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Population Health |
en |
pubs.org-id |
Gen.Practice& Primary Hlthcare |
en |
pubs.org-id |
Health Systems |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Paediatrics Child & Youth Hlth |
en |
pubs.org-id |
Psychological Medicine Dept |
en |
dc.identifier.eissn |
1097-6833 |
en |
pubs.record-created-at-source-date |
2019-07-08 |
en |
pubs.dimensions-id |
29625731 |
en |